Skip to content

Subscribe Follow on LinkedIn

Archive

January 2026

20: Building for zero failure: How 4G Clinical is redefining trial supply management

January 2026

19: How DNAnexus is enabling precision medicine from research to the point of care

January 2026

16: ‘The moat is data’: Marc Tessier-Lavigne on building an AI-native drug company

January 2026

15: ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% Increase Year-Over-Year

January 2026

15: Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

January 2026

15: The long game in cancer screening: Freenome’s data-first strategy

January 2026

15: Sun Pharma Announces the Availability of UNLOXCYT™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)

January 2026

14: Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ

January 2026

14: Why Trevi Therapeutics’ Jennifer Good believes treating cough means targeting the brain

January 2026

13: ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination with Checkpoint Inhibitors in Non-Small Cell Lung Cancer

January 2026

13: Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium

January 2026

13: Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

January 2026

13: Inside nChroma Bio’s push to deliver a functional cure for Hepatitis B

January 2026

12: NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security

January 2026

12: IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares’ Automated Platforms

January 2026

12: Cellares Expands Global Smart Factory Network With European Headquarters in the Netherlands

January 2026

12: Vibrant Therapeutics Raises $61M and Appoints Han Lee, Ph.D. as Co-CEO

January 2026

12: Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference

January 2026

12: Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference

January 2026

12: Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference

January 2026

12: Geron Corporation Provides 2026 Financial Guidance

January 2026

12: Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

January 2026

12: How Quince plans to scale a rare-disease platform built on patients’ own blood

January 2026

9: Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference

January 2026

9: How Genomenon finds order in 11 million scientific papers

January 2026

9: Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium

January 2026

9: Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

January 2026

9: Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”

January 2026

8: Massachusetts biopharma pipeline surges 14% as companies double down on innovation

January 2026

8: Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families

January 2026

8: Cellares and City of Hope to Automate Manufacturing of Solid Tumor CAR T Cell Therapy

January 2026

8: The physics mindset behind one of biotech’s fastest-growing diagnostics companies

January 2026

7: Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

January 2026

7: Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

January 2026

7: Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

January 2026

7: The first inning of a new research paradigm: Emulate, Inc. and the rise of organ-on-a-chip technology

January 2026

7: Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 2026

6: MassBio and Kendall Square Association Announce Strategic Partnership

January 2026

6: Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform

January 2026

6: SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer

January 2026

6: Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

January 2026

6: DemeRx Announces Successful Completion of Multiple Ascending Dose Clinical Trial of DMX-1001 for the Treatment of Alcohol Use Disorder (AUD)

January 2026

6: 3T Biosciences Announces Appointments of Behzad Kharabi, M.D., as Chief Medical Officer, and Parker Institute for Cancer Immunotherapy (PICI) CEO Karen Knudsen, MBA, Ph.D., to Board of Directors

January 2026

5: Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 2026

2: FDA approvals - December 2025

December 2025

29: ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of the “100 Most Influential People in Oncology in 2025”

December 2025

29: Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

December 2025

22: enGene Reports Full Year 2025 Financial Results and Provides Business Update

December 2025

22: Sinaptica Therapeutics Completes Scientific Advisory Board, Bringing Together Leading Voices Across Patients, Science, Medicine, and Commercial Strategy

December 2025

18: Verily-led consortium secures $9.2M NIH award extension for platform to advance systems biology research

December 2025

18: Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 2025

18: Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 2025

17: Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

December 2025

17: Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 2025

16: ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer

December 2025

16: nChroma Bio Receives Authorization of Clinical Trial Application to Initiate First-in-Human Study for Epigenetic Silencer CRMA-1001 for the Treatment of Chronic Hepatitis B

December 2025

15: Kyverna Therapeutics Announces Proposed Public Offering of Common Stock

December 2025

15: Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

December 2025

14: Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

December 2025

12: Onyx @ Jefferies: Ali Pashazadeh, CEO, Treehill Partners

December 2025

12: ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe

December 2025

12: Jefferies Healthcare Conference 2025 - Onyx Roundup | London Life Sciences Week 2025

December 2025

11: Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.

December 2025

11: Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation

December 2025

11: Sinaptica Therapeutics Receives Funding from The Centre for Aging + Brain Health Innovation and Baycrest to Advance Breakthrough Neuromodulation Therapy for Alzheimer’s

December 2025

10: Onyx @ Jefferies: Lubor Gaal, CFO, Circio

December 2025

10: Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

December 2025

10: Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851

December 2025

9: Onyx @ Jefferies: David Chang, CEO, Allogene

December 2025

9: Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy

December 2025

8: Lexicon’s next act: betting big on first-in-class cardiometabolic medicine

December 2025

8: Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS

December 2025

8: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

December 2025

6: Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025

December 2025

5: Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

December 2025

5: Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium

December 2025

5: Onyx @ Jefferies: David Hung, CEO, Nuvation Bio

December 2025

4: Onyx @ Jefferies: Jon Rees, CEO, MitoRx

December 2025

4: Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium

December 2025

3: “Speed is survival”: inside 4D Molecular Therapeutics’ bid to scale genetic medicine

December 2025

3: VeriSIM Life Wins Prestigious AI in Action Award at Reuters Global Pharma Awards

December 2025

3: Onyx @ Jefferies: Warner Biddle, CEO, Kyverna Therapeutics

December 2025

2: FDA Approvals - November 2025

December 2025

2: MassBio and SCbio launch Drive application for spring cohort

December 2025

2: enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness

December 2025

2: Alzheon Announces Peer-Reviewed Publication Providing Evidence for Hippocampal Volume as Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Alzheimer’s Disease

December 2025

1: Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares

December 2025

1: Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares

December 2025

1: New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease

December 2025

1: Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

December 2025

1: Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO

December 2025

1: Nature Genetics Study Validates Seer’s Proteograph Platform as Essential for Turning Genetic Signals Into Reliable Drug Targets and Biomarkers

November 2025

27: Legend Biotech Awarded 2025 FIBA Foreign Investor of the Year by Flanders Investment & Trade

November 2025

26: Affinia closes $40m Series C: CEO Rick Modi explains how low-dose gene therapy capsids could cure cardiomyopathy

November 2025

25: Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

November 2025

25: Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

November 2025

25: enGene to Present at the Piper Sandler 37th Annual Healthcare Conference

November 2025

25: Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

November 2025

24: Belite Bio Announces Agreement to Assign Exclusive License Agreement with Columbia University to Belite Swiss

November 2025

20: Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference